Sodium hyaluronate cross-linked manufacturers

Filters

Filters

Filters , active

Country of origin : India
None products found

sodium hyaluronate cross-linked

Injection, pre-filled syringe 1.5 %, 3 % - 2 ml, 3 ml, 4 ml, 5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #2303
A pharmaceutical manufacturer with over 25 years of experience that develops and produces fixed-dose and single-entity generic and specialty pharmaceutical products. The company offers an extensive range of injectable dosage forms, including parenterals, and also manufactures oral solids. Its facilities operate under recognised international quality certifications such as EU-GMP, ANVISA, PIC/S and TGA approvals, supporting reliable large-scale production of pharmaceutical products for global export while emphasizing efficacy, affordability and consistent quality.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About sodium hyaluronate cross-linked

Sodium hyaluronate cross-linked manufacturers include Allergan Aesthetics (Juvéderm), Galderma (Restylane), Teoxane, Merz and Sanofi (Synvisc), plus raw material producers such as Bloomage Biotech in China. Cross-linked sodium hyaluronate is hyaluronic acid whose chains are chemically linked to form a long-lasting gel. It is used mainly in dermal fillers for facial volume and wrinkles, and in joint injections (viscosupplements) for knee osteoarthritis. These products are usually regulated as medical devices. Companies can source cross-linked hyaluronic acid gels and finished products through supply, private label or licensing.

Sodium hyaluronate cross-linked key facts

Property

Sodium hyaluronate cross-linked

Name

Cross-linked sodium hyaluronate; cross-linked hyaluronic acid (HA)

Source of HA

Bacterial fermentation (mainly Streptococcus species)

Common cross-linkers

BDDE (1,4-butanediol diglycidyl ether) for most fillers; divinyl sulfone (hylan G-F 20)

Main uses

Dermal fillers; intra-articular viscosupplements for osteoarthritis

Filler brands

Juvéderm (Allergan Aesthetics / AbbVie); Restylane (Galderma); Teosyal (Teoxane); Belotero (Merz)

Viscosupplement brands

Synvisc, Synvisc-One (hylan G-F 20, Sanofi); Durolane; Monovisc

Dosage form

Sterile gel in prefilled syringes, often with lidocaine (fillers)

Regulatory class

Medical device: EU Class III (MDR); US PMA (Class III)

Indications (fillers)

Correction of facial wrinkles and folds; lip and facial volume restoration

Indications (viscosupplements)

Pain from knee osteoarthritis not responding to other treatment

Raw material producers

Bloomage Biotech and other Chinese producers; European and Japanese producers

Generic status

Not applicable; each product approved separately as a device

Sodium hyaluronate cross-linked manufacturers and licensing history

Cross-linked hyaluronic acid became widely used in medicine in the 1990s. Hylan G-F 20 (Synvisc), a joint injection for knee osteoarthritis, was approved in the US in 1997. Restylane, developed by Q-Med and now owned by Galderma, became the first HA dermal filler approved in the US in 2003, followed by Juvéderm.

The dermal filler market is led by Allergan Aesthetics (part of AbbVie) and Galderma, with Teoxane, Merz and many Korean and Chinese producers. Most hyaluronic acid raw material is now produced in China by fermentation, with Bloomage Biotech among the largest producers.

Products differ in HA concentration, cross-linking degree, particle size and gel strength, which affect how long they last. Buyers should confirm medical device certification (CE mark under MDR or FDA PMA), residual BDDE levels, endotoxin data and clinical evidence before choosing a supplier.

Sodium hyaluronate cross-linked dosage forms and dossier types

Cross-linked sodium hyaluronate is supplied as sterile gels in prefilled syringes.

Form

Strengths

Typical dossier

Notes

HA dermal filler gel

Typically 15–25 mg/ml HA; often 0.3% lidocaine

EU MDR Class III; US PMA

Main aesthetic form

HA viscosupplement (single or multiple injection)

Per product

EU MDR Class III; US PMA

Knee osteoarthritis

Cross-linked HA bulk gel / raw HA

Bulk

Supplier documentation; device master file

Medical or cosmetic grade

Target market

Dossier format

Key requirement

European Union

MDR technical documentation (Class III)

Notified body review; clinical evaluation

United States

PMA

Clinical trials per indication

China, Korea, other markets

National device registration

Local clinical data often required

Sodium hyaluronate cross-linked regulatory and patent status

Cross-linked hyaluronic acid products are usually regulated as Class III medical devices. In the EU, they need CE marking under the Medical Device Regulation, with notified body review and clinical evaluation. In the US, they need premarket approval (PMA). Each product is approved separately, and cross-linking technologies are often protected by patents.

Sodium hyaluronate cross-linked mechanism of action and therapeutic use

Hyaluronic acid binds large amounts of water. Cross-linking makes it resist breakdown, so it stays in place for months. In dermal fillers, it adds volume and smooths wrinkles, lasting about 6–18 months. In joints, it improves the lubricating and shock-absorbing properties of joint fluid, which can reduce knee osteoarthritis pain. The effect can be reversed with the enzyme hyaluronidase.

Sodium hyaluronate cross-linked licensing and sourcing

Cross-linked sodium hyaluronate suppliers typically offer finished device supply, private label, regional distribution or raw material supply. Buyers usually compare device certification, clinical data, gel properties and territory availability. Current offers and supplier contacts are listed among the sodium hyaluronate cross-linked manufacturers on Pipelinepharma.

Frequently asked questions about sodium hyaluronate cross-linked

Who are the main cross-linked sodium hyaluronate manufacturers? Allergan Aesthetics (Juvéderm), Galderma (Restylane), Teoxane and Merz lead in dermal fillers. Sanofi makes Synvisc for joints, and Bloomage Biotech is a major raw material producer.

Is cross-linked hyaluronic acid a drug or a device? In the EU and US, most cross-linked HA fillers and joint injections are regulated as Class III medical devices.

What is the difference between cross-linked and non-cross-linked hyaluronic acid? Cross-linked HA is chemically linked into a gel that lasts for months. Non-cross-linked HA breaks down quickly and is used in eye drops, skin care and some joint injections.

What is BDDE? BDDE (1,4-butanediol diglycidyl ether) is the most common cross-linker in HA fillers. Residual BDDE levels must be tightly controlled.

How long do cross-linked hyaluronic acid fillers last? Most HA fillers last about 6–18 months, depending on the product and treatment area.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.